Revolution Medicines reported Phase 3 success for daraxonrasib (RAS inhibitor) in metastatic pancreatic ductal adenocarcinoma, saying the drug met survival and progression endpoints in a registrational study. The company said interim results were determined to be final, with daraxonrasib delivering a median overall survival of 13.2 months versus 6.7 months for chemotherapy. Revolution said it plans to submit to regulators and that the program has already received an FDA “national priority” voucher, a designation designed to accelerate review timelines. The readout immediately sharpened attention on RAS(ON) strategies for a tumor type where targeted options remain limited. Analysts and investors are now focused on how much of the effect is driven by biomarker-defined subgroups, since the company did not release all primary endpoint details in the initial communications.